• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by ArriVent BioPharma Inc.

    4/28/26 4:10:28 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVBP alert in real time by email
    DEFA14A 1 tm261626d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 

    (Amendment No.  )

     

    Filed by the Registrant x

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement
    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨Definitive Proxy Statement
    xDefinitive Additional Materials
    ¨Soliciting Material Under §240.14a-12

     

    ArriVent BioPharma, Inc.

     

    (Name of Registrant as Specified In Its Charter)

     

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    xNo fee required
    ¨Fee paid previously with preliminary materials
    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

    GRAPHIC

    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V96463-P51036 ARRIVENT BIOPHARMA, INC. 18 CAMPUS BOULEVARD SUITE 100 NEWTOWN SQUARE, PENNSYLVANIA 19073 UNITED STATES ARRIVENT BIOPHARMA, INC. 2026 Annual Meeting Vote by June 17, 2026 11:59 PM ET You invested in ARRIVENT BIOPHARMA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 18, 2026. Vote Virtually at the Meeting* June 18, 2026 12:00 p.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/AVBP2026 *Please check the meeting materials for any special requirements for meeting attendance. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V96464-P51036 1. Election of Directors For Nominees: 01) James Healy, M.D., Ph.D. 02) John Hohneker, M.D. 03) Stuart Lutzker, M.D., Ph.D. 2. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof. THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

     

    Get the next $AVBP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVBP

    DatePrice TargetRatingAnalyst
    3/12/2026$42.00Buy
    BTIG Research
    12/10/2025$45.00Buy
    BTIG Research
    11/25/2025$43.00Buy
    Truist
    7/10/2025$33.00Buy
    Goldman
    3/20/2025$37.00Buy
    B. Riley Securities
    3/10/2025$45.00Buy
    Guggenheim
    7/22/2024$35.00Outperform
    Oppenheimer
    4/30/2024$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $AVBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ArriVent BioPharma Reports First Quarter 2026 Financial Results

    Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent ADC, advances into the clinic and plans to dose its first patient in 2H 2026, initially for ovarian and endometrial cancers ARR-002's superior anti-tumor activity and favorable tolerability vs. single-target or bivalent approaches in preclinical ovarian cancer models presented at AACRCash and investments of $326.4 million as of March 31, 2026 expected to fund operations into 4Q 2027 NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP

    5/11/26 4:01:00 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

    Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in

    5/7/26 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

    Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable tolerability underscores best-in-disease ADC potential NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) A

    3/17/26 5:00:00 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Lachapelle Robin

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    2/4/26 8:44:13 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President of R&D Lutzker Stuart

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    2/4/26 8:43:08 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Kung Winston

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    2/4/26 8:41:12 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research resumed coverage on ArriVent BioPharma with a new price target

    BTIG Research resumed coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $42.00

    3/12/26 8:49:18 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on ArriVent BioPharma with a new price target

    BTIG Research initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $45.00

    12/10/25 8:24:33 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on ArriVent BioPharma with a new price target

    Truist initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $43.00

    11/25/25 8:38:45 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    SEC Filings

    View All

    ArriVent BioPharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

    5/11/26 4:43:06 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by ArriVent BioPharma Inc.

    424B5 - ArriVent BioPharma, Inc. (0001868279) (Filer)

    5/11/26 4:41:13 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by ArriVent BioPharma Inc.

    10-Q - ArriVent BioPharma, Inc. (0001868279) (Filer)

    5/11/26 4:08:45 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $AVBP
    Leadership Updates

    Live Leadership Updates

    View All

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    12/4/24 4:32:39 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    11/14/24 4:33:47 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    11/12/24 2:45:16 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Reports Third Quarter 2025 Financial Results

    Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in ChinaEstablised commercial leadership within excutive team with appointment of Brent S. Rice as Chief Commercial OfficerCash and investments of $305.4 million as of September 30, 2025 expected to fund operations into mid-2027 NEWTOWN SQUARE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. ("Company" or "ArriVent") (Nasdaq: "AVBP"), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical

    11/10/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent Appoints Brent S. Rice as Chief Commercial Officer

    NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. "Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent. "We are excited to welcome h

    9/22/25 4:05:00 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Reports First Quarter 2025 Financial Results

    Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results

    5/12/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care